Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7422552 | 0.98 | ADRA2C (0.65) | ADRA2CALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL2007035 | 0.87 | MEN1 (0.76) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL54737 | 0.86 | KMT2A (0.69) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL31590799 | 0.86 | KMT2A (0.69) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL4593391 | 0.85 | MAPT (0.73) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL4780753 | 0.84 | SMN1; SMN2 (0.72) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL14899353 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL31522181 | 0.84 | ADRA2C (0.72) | ADRA2CALDH1A1MAPTHSD17B10LMNA | |
| SCHEMBL19026947 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPTHSD17B10LMNAUSP2 | |
| SCHEMBL3129403 | 0.83 | ALDH1A1 (0.65) | ALDH1A1MAPTHSD17B10LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4665239-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-11040939-B1 | N-transfer reagent and method for preparing the same and its application | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2021-06-22 | — | — | US | disclosed |
| EP-1957498-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2017-02-15 | — | — | EP | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1071668-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | Du Pont Pharmaceuticals Company (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054308-A1 | 5-AMINOINDENO(1,2-C)PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040939-B1 | N-transfer reagent and method for preparing the same and its application | DNTT, NNMT, NMT1 | ADRA2C 4130/4885ALDH1A1 1050/4885MAPT 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.